Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
Isa Oboirien, Higher Specialty Trainee at Health Education England, shared a post on LinkedIn:
“Why might Factor XI inhibition work differently in stroke and ACS?
The contrasting signals with factor XIa inhibition may reflect differences in thrombotic biology.
Recurrent coronary events after ACS are predominantly platelet-driven, arising from plaque rupture or erosion with intense platelet activation.
Contemporary PCI and potent dual antiplatelet therapy already target this pathway effectively, potentially leaving little residual coagulation-mediated risk for additional FXIa inhibition to modify.
Indeed, LIBREXIA-ACS showed no reduction in cardiovascular death, MI or ischaemic stroke with milvexian.
In contrast, recurrent ischaemic stroke is mechanistically heterogeneous, involving artery-to-artery thromboembolism, thrombin generation and fibrin-rich clot propagation, alongside platelet activation.
FXI may therefore contribute more importantly to thrombus amplification within cerebral circulation.
The encouraging symptomatic-stroke signal in AXIOMATIC-SSP and OCEANIC-STROKE trials, coupled with minimal intracranial bleeding, raises the intriguing possibility that FXIa inhibition may be better suited to cerebral than coronary thrombosis – a hypothesis that LIBREXIA-STROKE will ultimately test.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe LippiÖ‰ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question